Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SRPK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SRPK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SRPK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SRPK2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SRPK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SRPK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SRPK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SRPK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SRPK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SRPK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SRPK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578716 | Skin | AK | positive regulation of cell cycle | 58/1910 | 313/18723 | 5.08e-06 | 1.19e-04 | 58 |
GO:001820910 | Skin | AK | peptidyl-serine modification | 61/1910 | 338/18723 | 7.00e-06 | 1.55e-04 | 61 |
GO:001810516 | Skin | AK | peptidyl-serine phosphorylation | 57/1910 | 315/18723 | 1.27e-05 | 2.57e-04 | 57 |
GO:007099728 | Skin | AK | neuron death | 63/1910 | 361/18723 | 1.50e-05 | 2.94e-04 | 63 |
GO:190121425 | Skin | AK | regulation of neuron death | 57/1910 | 319/18723 | 1.87e-05 | 3.52e-04 | 57 |
GO:005079226 | Skin | AK | regulation of viral process | 34/1910 | 164/18723 | 4.45e-05 | 7.03e-04 | 34 |
GO:004507010 | Skin | AK | positive regulation of viral genome replication | 11/1910 | 30/18723 | 1.05e-04 | 1.38e-03 | 11 |
GO:190390026 | Skin | AK | regulation of viral life cycle | 30/1910 | 148/18723 | 1.85e-04 | 2.12e-03 | 30 |
GO:190121626 | Skin | AK | positive regulation of neuron death | 22/1910 | 97/18723 | 2.51e-04 | 2.72e-03 | 22 |
GO:004506920 | Skin | AK | regulation of viral genome replication | 19/1910 | 85/18723 | 7.79e-04 | 6.50e-03 | 19 |
GO:004352318 | Skin | AK | regulation of neuron apoptotic process | 35/1910 | 212/18723 | 2.90e-03 | 1.84e-02 | 35 |
GO:005140220 | Skin | AK | neuron apoptotic process | 39/1910 | 246/18723 | 3.62e-03 | 2.17e-02 | 39 |
GO:004352522 | Skin | AK | positive regulation of neuron apoptotic process | 13/1910 | 58/18723 | 4.89e-03 | 2.77e-02 | 13 |
GO:00062605 | Skin | AK | DNA replication | 40/1910 | 260/18723 | 5.49e-03 | 3.03e-02 | 40 |
GO:0022618112 | Skin | SCCIS | ribonucleoprotein complex assembly | 27/919 | 220/18723 | 1.11e-05 | 3.87e-04 | 27 |
GO:0071826112 | Skin | SCCIS | ribonucleoprotein complex subunit organization | 27/919 | 227/18723 | 1.96e-05 | 5.92e-04 | 27 |
GO:0022613112 | Skin | SCCIS | ribonucleoprotein complex biogenesis | 44/919 | 463/18723 | 2.23e-05 | 6.50e-04 | 44 |
GO:0016032112 | Skin | SCCIS | viral process | 40/919 | 415/18723 | 3.80e-05 | 9.88e-04 | 40 |
GO:1903311111 | Skin | SCCIS | regulation of mRNA metabolic process | 30/919 | 288/18723 | 8.73e-05 | 1.99e-03 | 30 |
GO:0019058112 | Skin | SCCIS | viral life cycle | 32/919 | 317/18723 | 9.37e-05 | 2.10e-03 | 32 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRPK2 | SNV | Missense_Mutation | novel | c.736N>A | p.Glu246Lys | p.E246K | P78362 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
SRPK2 | SNV | Missense_Mutation | | c.536N>C | p.Val179Ala | p.V179A | P78362 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPK2 | SNV | Missense_Mutation | | c.406N>A | p.Glu136Lys | p.E136K | P78362 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
SRPK2 | insertion | Frame_Shift_Ins | novel | c.1735_1736insTAGAGAGTGCTGTGTGGAGA | p.Trp579LeufsTer39 | p.W579Lfs*39 | P78362 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPK2 | insertion | Nonsense_Mutation | novel | c.964_965insATTGAATGTAAGTTGCCTTGGTCATCACAATCCATGTAAAGGAG | p.Pro322HisfsTer2 | p.P322Hfs*2 | P78362 | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SRPK2 | SNV | Missense_Mutation | | c.169N>C | p.Glu57Gln | p.E57Q | P78362 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.57G>T | p.Glu19Asp | p.E19D | P78362 | protein_coding | tolerated(0.33) | benign(0.388) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.277N>T | p.His93Tyr | p.H93Y | P78362 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | novel | c.766N>T | p.Pro256Ser | p.P256S | P78362 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.169N>C | p.Glu57Gln | p.E57Q | P78362 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |